CAPTRUST Financial Advisors
BNGO icon

CAPTRUST Financial Advisors’s Bionano Genomics BNGO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$2K – 2311
2022
Q2 		$2K Hold
2
– – ﹤0.01% 4428
2022
Q1 		$4K Sell
2
-2
-50% -$2.7K ﹤0.01% 4229
2021
Q4 		$8K Hold
4
– – ﹤0.01% 3833
2021
Q3 		$15K Sell
4
-1
-20% -$3.5K ﹤0.01% 3342
2021
Q2 		$20K Hold
5
– – ﹤0.01% 3103
2021
Q1 		$26K Buy
+5
New +$28.2K ﹤0.01% 2832
2020
Q4 		– Hold
0
– – – 3404
2020
Q3 		– Hold
0
– – – 3058
2020
Q2 		– Hold
0
– – – 2846

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CAPTRUST Financial Advisors's BNGO Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Bionano Genomics (BNGO) in Q3 2022, closing a stake of 2 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in BNGO in Q1 2021 and held it in 6 quarters. The position peaked at $26K in Q1 2021. 140 funds tracked by Wall St. Rank hold BNGO as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Bionano Genomics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 2 Bionano Genomics shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Bionano Genomics in Q1 2021 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's Bionano Genomics position peaked at $26K in Q1 2021.
  • 140 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.